ACTU
Actuate Therapeutics, Inc. Common stock
NASDAQ: ACTU · HEALTHCARE · BIOTECHNOLOGY
$2.88
-0.69% today
Updated 2026-04-29
Market cap
$68.29M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.06
Dividend yield
—
52W range
$2 – $12
Volume
0.1M
Actuate Therapeutics, Inc. Common stock (ACTU) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Gross margin | — | — | — | — |
| R&D | $16.39M | $21.71M | $18.68M | $10.29M |
| SG&A | $3.82M | $3.27M | $6.48M | $12.20M |
| Operating income | $-20.21M | $-24.97M | $-25.16M | $-22.50M |
| Operating margin | — | — | — | — |
| EBITDA | $-20.08M | $-24.43M | $-25.16M | $-22.50M |
| EBITDA margin | — | — | — | — |
| EBIT | $-20.14M | $-24.70M | $-27.30M | — |
| Interest expense | $16200.00 | $43641.00 | $18717.00 | $20250.00 |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-20.16M | $-24.74M | $-27.29M | $-22.23M |
| Net income growth (YoY) | — | -22.7% | -10.3% | +18.5% |
| Profit margin | — | — | — | — |